| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HRASLS3 |
| Uniprot No | P53816 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 12-132aa |
| 氨基酸序列 | DLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSALTDKAIVK KELLYDVAGSDKYQVNNKHDDKYSPLPCSKIIQRAEELVGQEVLYKLTSE NCEHFVNELRYGVARSDQVRD |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HRASLS3重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*HRASLS3. a lipid metabolism regulator, exhibits antitumor activity in colorectal cancer*
**作者**：Li Y, et al.
**摘要**：该研究通过重组HRASLS3蛋白实验，发现其通过抑制脂肪酸合成酶(FASN)活性，阻断脂质代谢通路，从而抑制结直肠癌细胞增殖并诱导凋亡，揭示其潜在的肿瘤抑制功能。
2. **文献名称**：*Structural and functional characterization of HRASLS3 as a phospholipase A1/2*
**作者**：Uyama T, et al.
**摘要**：作者解析了重组HRASLS3蛋白的晶体结构，证实其具有磷脂酶A1/A2双重活性，并通过定点突变实验鉴定了催化关键位点，为理解其脂质修饰功能提供分子机制依据。
3. **文献名称**：*HRASLS3 modulates adipocyte differentiation via retinoic acid receptor signaling*
**作者**：Li Z, et al.
**摘要**：研究发现重组HRASLS3蛋白通过结合视黄酸受体(RAR)，调控脂肪细胞分化相关基因表达，提示其在代谢疾病(如肥胖)中的调控作用，可能与脂滴形成相关。
注：以上文献为示例，实际引用需根据具体研究内容选择合适论文。
HRASLS3 (HRAS-like suppressor 3), also known as PLA2G16 or H-REV107. is a member of the HRASLS (HRL) family of proteins, which share structural homology with the Ras GTPase superfamily but lack intrinsic GTPase activity. Initially identified as a tumor suppressor, HRASLS3 is implicated in regulating cell proliferation, differentiation, and apoptosis, particularly through its interaction with oncogenic Ras signaling pathways. The protein is characterized by an N-terminal acyltransferase/phospholipase A1 (PLA1) domain, enabling enzymatic activity in lipid metabolism, and a C-terminal domain involved in membrane association and protein-protein interactions.
HRASLS3 plays a dual role in lipid remodeling and tumor suppression. Its phospholipase activity contributes to the hydrolysis of phospholipids, influencing membrane dynamics, lipid droplet formation, and signaling pathways. Studies link HRASLS3 dysregulation to cancer progression, obesity, and metabolic disorders. For instance, reduced HRASLS3 expression correlates with poor prognosis in certain cancers, while its overexpression suppresses tumor growth by inducing apoptosis or inhibiting Ras-mediated oncogenesis.
Recombinant HRASLS3 protein is typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems to study its biochemical properties, structure-function relationships, and therapeutic potential. Purified recombinant HRASLS3 is utilized in enzymatic assays to characterize lipid-modifying activities, screen inhibitors, or explore its role in cellular pathways via *in vitro* models. Its tumor-suppressive and metabolic regulatory functions make it a candidate for targeted drug development. Research also investigates its involvement in inflammation and viral infections, as some studies suggest interactions with viral entry mechanisms. Overall, HRASLS3 represents a multifunctional protein bridging lipid biology and disease pathogenesis.
×
